Iwane Matsui President Kensuke Iizuka Managing Executive Officer, CFO PLAY LIST from the beginning Business Results Fiscal Year Ended March 31, 2026 Disclaimer Our Approach under the New Management Structure Index 1. Executive Summary Executive Summary (Fiscal Year Ended March 31, 2026) Executive Summary (Forecast for Fiscal Year Ending March 31, 2027) 2. Business Results, Fiscal Year Ended March 31, 2026 Financial Highlights (Year on Year) Breakdown of Net Sales (by Business and Field) Breakdown of Net Sales (by Destination and Product Type) Information by Destination (Americas) Information by Destination (EMEA) Information by Destination (China Outlook for China Changes in the Testing Market Environment in China Information by Destination (AP) Information by Destination (Japan) Breakdown of Operating Profit (Year on Year) Goodwill Impairment Losses at Consolidated Subsidiaries Breakdown of Changes in the Consolidated Statement of Financial Position Cash Flows Proposed Dividend for the Fiscal Year Ended March 31, 2026 3. Strategic Themes under the Mid-Term Management Plan Accelerated Rollouts in the Hemostasis Field Business Expansion in Emerging Markets Strengthening the Competitiveness of the Diagnostics Business Succession and Future Expansion in the Clinical Chemistry Field Initiatives to Improve Profitability Enhance Profitability through Reforms to the Value Chain Review the Business Portfolio 4. Financial Forecast for the Fiscal Year Ending March 31, 2027 Financial Forecast for the Fiscal Year Ending March 31, 2027 Breakdown of Net Sales and Operating Profit for the Fiscal Year Ending March 31, 2027 Capital Allocation (Outlook for the Fiscal Year Ending March 31, 2027) Dividend Forecast for the Fiscal Year Ending March 31, 2027 (Appendix) Quarterly Results for the Fiscal Year Ended March 31, 2026 Financial Forecast for the Fiscal Year Ending March 31, 2027 (Sales by Business, Field, and Destination) Highlights (April 2025 to April 2026) Together for a better healthcare journey Back Next